Stent developer TriVascular Technologies sets terms for $91 million IPO

By
A A A

TriVascular Technologies, which develops new stent grafts for endovascular aortic repair ( EVAR ), announced terms for its IPO on Thursday. The Santa Rosa, CA-based company plans to raise $91 million by offering 6.5 million shares at a price range of $13 to $15. At the midpoint of the proposed range, it would command a fully diluted market value of $284 million.

TriVascular Technologies, which was founded in 1998 and booked $20 million in sales for the fiscal year ended December 31, 2013, plans to list on the NASDAQ under the symbol TRIV. It initially filed confidentially on December 16, 2013. J.P. Morgan and Credit Suisse are the joint bookrunners on the deal.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: EVAR , TRIV

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Budgeting for Baby
Budgeting for Baby                  
A Home to Retire In
A Home to Retire In                 

Stocks

Referenced

Most Active by Volume

60,888,367
  • $16.905 ▼ 0.85%
47,560,442
  • $13.336 ▼ 6.02%
41,175,872
  • $76.38 ▼ 3.37%
39,079,578
  • $14.58 ▼ 1.42%
38,307,542
  • $97.22 ▼ 1.59%
34,894,382
  • $3.413 ▼ 2.21%
33,711,083
  • $99.14 ▼ 1.60%
30,546,913
  • $25.01 ▼ 0.64%
As of 10/1/2014, 02:16 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com